Current treatment landscape for relapsed and/or refractory multiple myeloma

@article{Dimopoulos2015CurrentTL,
  title={Current treatment landscape for relapsed and/or refractory multiple myeloma},
  author={Meletios Athanasios Dimopoulos and Paul G Richardson and Philippe Moreau and Kenneth C. Anderson},
  journal={Nature Reviews Clinical Oncology},
  year={2015},
  volume={12},
  pages={42-54}
}
Recent developments in the treatment of multiple myeloma have led to improvements in response rates and to increased survival; however, relapse is inevitable in almost all patients. Recurrence of myeloma is typically more aggressive with each relapse, leading to the development of treatment-refractory disease, which is associated with a shorter survival. Several phase II and III trials have demonstrated the efficacy of recently approved agents in the setting of relapsed and/or refractory… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS